IPO Watch: Epocrates

<i>

The analyst believes that the competition could eventually overwhelm ePocrates. "EPocrates is popular today," Garcia says. "If they will be successful 10 years down the road—I don't think so."

</i>

I second that. There are lot of richer alternatives to Epocrates even right now. Trying to defend the loyalty with just a free drug information database won't cut it. physician market is complex and fickle with so many specialties and such.

Looking at the red herring, the earnings of $25mil includes $21 mil from tax benefits (from losses in the prior years) - so the operating net is about $4mil. Am I missing something?

jon applebaum of IL 4:46PM May 15, 2008